January - 2022

Companies in the News

eFFECTOR Therapeutics Provides Pipeline and Business Updates

Tomivosertib development strategy updated, including addition of a new cohort in Phase 2b KICKSTART trial in non-small cell lung cancer...

Nuvation Bio Announces FDA Clearance of IND Application for NUV-868 for the Advanced Solid Tumors

NEW YORK, Jan. 20, 2022 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet...

Amgen chooses Generate in $1.9B biobucks deal to churn out up to 10 multispecific drugs

Amgen wants its future drugs to be multispecific, and so the biopharmaceutical company selected Generate Biomedicines for a $1.9 billion...